Cyramza Solution
Product Images NDC 0002-7678

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Cyramza (NDC 0002-7678). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eli Lilly And Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Package Carton – Cyramza 100 mg/10 mL Single-use Vial (Cyramza 100mg Carton 001 02)

Packaging label for CYRAMZA (ramucirumab) Injection, 100 mg/10 mL (10 mg/mL) solution for intravenous infusion. The label indicates a single-dose vial, instructions for dilution before use, storage at 2°–8°C, and that it is made by Eli Lilly and Company, Indianapolis, IN.*

FDA Label Image

Package Carton – Cyramza 100 mg/50 mL Single-use Vial (Cyramza 100mg Carton 003 01)

Packaging label for CYRAMZA (ramucirumab) Injection 100 mg/10 mL (10 mg/mL) solution for intravenous infusion. The label indicates storage instructions, contents of the vial, and usage directions. It includes the Eli Lilly and Company logo, address, and other regulatory information.*

FDA Label Image

Package Carton – Cyramza 500 mg/50 mL Single-use Vial (Cyramza 500mg Carton 000 02)

Packaging label for CYRAMZA (ramucirumab) Injection 500 mg/50 mL (10 mg/mL) solution for intravenous use by Eli Lilly and Company. The label includes dosage form and strength, storage instructions to refrigerate at 2°–8°C, warnings not to freeze or shake, and directions to use as a single-dose vial with dilution prior to infusion. It also lists active ingredients, inactive ingredients, and company information with the Lilly logo.*

FDA Label Image

Package Carton – Cyramza 500 mg/50 mL Single-use Vial (Cyramza 500mg Carton 004 01)

Packaging label for CYRAMZA (ramucirumab) injection, 500 mg/50 mL (10 mg/mL) solution for intravenous use. The label shows product name, strength, dosage form, storage instructions to refrigerate at 2°–8°C, and preparation directions. It includes manufacturer information for Eli Lilly and Company and the NDC 0002-7678-01. The label notes the product is a single-dose vial requiring dilution prior to use.*

FDA Label Image

Figure 1 (Cyramza Pi F001 V2)

A Kaplan-Meier survival curve comparing the probability of overall survival over 28 months between CYRAMZA (ramucirumab) and placebo groups. The solid line represents CYRAMZA, and the dotted line represents placebo. A table below the graph lists the number of patients at risk at various time points for both groups.*

FDA Label Image

Figure 2 (Cyramza Pi F002 V2)

This is a Kaplan-Meier survival curve depicting the probability of overall survival over time in months following randomization. The graph compares two treatment groups: CYRAMZA (ramucirumab) plus Paclitaxel, represented by a solid line, and Placebo plus Paclitaxel, represented by a dotted line. The x-axis shows time in months, and the y-axis shows the probability of overall survival. A table below the graph indicates the number of patients at risk at various time points for each group.*

FDA Label Image

Figure 3 (Cyramza Pi F003 V2)

A Kaplan-Meier survival curve chart showing the probability of progression-free survival over time in months from randomization. The chart compares two groups: one treated with CYRAMZA plus Erlotinib (solid line) and the other with Placebo plus Erlotinib (dotted line). The x-axis represents time from randomization in months, and the y-axis represents the probability of progression-free survival, ranging from 0.0 to 1.0. A risk table below the x-axis displays the number of patients at risk at various time points for each treatment group.*

FDA Label Image

Figure 4 (Cyramza Pi F004 V2)

A Kaplan-Meier survival curve showing the probability of overall survival over time since randomization (in months) for two groups: CYRAMZA plus Docetaxel and Placebo plus Docetaxel. The graph includes the number of patients at risk at various time points for both groups. The CYRAMZA plus Docetaxel group is represented by a solid line, and the Placebo plus Docetaxel group by a dotted line.*

FDA Label Image

Figure 5 (Cyramza Pi F005 V2)

A Kaplan-Meier survival curve showing the probability of overall survival over time (months) since randomization, comparing CYRAMZA plus FOLFIRI versus placebo plus FOLFIRI treatment groups. The graph includes the number at risk at various time points for each group, with CYRAMZA plus FOLFIRI represented by a solid line and placebo plus FOLFIRI by a dotted line.*

FDA Label Image

Figure 6 (Cyramza Pi F006 V2)

A Kaplan-Meier survival curve graph depicting the probability of overall survival over time since randomization (in months) for CYRAMZA + BSC versus Placebo + BSC. The solid line represents CYRAMZA + BSC, and the dotted line represents Placebo + BSC, with corresponding numbers at risk shown below the x-axis for each time point, demonstrating survival trends up to 27 months.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.